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To determine the maximum-tolerated dose (MTD) and the recommended dose (RD) of paclitaxel administered weekly with a fixed
dose of cisplatin, and to assess the toxicity and activity of this combination, we conducted a phase I/II trial in patients with advanced
non-small-cell lung cancer (NSCLC). In this study, patients with stage IIIB/IV NSCLC were eligible. Paclitaxel, at a starting dose of
40mgm
 2week
 1 on days 1, 8, and 15, was combined with a fixed dose of cisplatin 80mgm
 2 on day 1. Chemotherapy was given
in a 4-week cycle. In this phase I/II study, 38 patients were enrolled. Dose-limiting toxicities (DLT) were neutropenia, fatigue, and
omission of treatment due to leucopenia, thrombocytopenia, or febrile neutropenia. The MTD and RD were estimated to be
70mgm
 2. Of the 37 assessable patients, 23 had a partial response and one had a complete response. Overall response rate was
62.1% (95% confidence interval (CI): 46.5–77.7%). The progression-free survival, the median survival time, and the 1-year survival
rate were 5.5 months, 13.7 months, and 56.9%, respectively. This regimen is tolerable and very active against advanced NSCLC, and
its efficacy should be confirmed in a phase III study.
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Lung cancer is a leading cause of cancer death in many
industrialised countries, with a 5-year survival rate of only 14%
(Wingo et al, 1995). Non-small-cell lung cancer (NSCLC) accounts
for approximately 75% of all lung cancer, and surgery offers the
best chance of cure and long-term survival. Unfortunately, the
majority of patients present with disease not amenable to surgery
because it is either locally advanced or has metastasised.
Chemotherapy for advanced NSCLC is often considered ineffective
or excessively toxic. However, meta-analyses have demonstrated
that chemotherapy results in a small improvement in survival and
quality of life for patients compared with supportive care alone
(Grilli et al, 1993; Marino et al, 1994).
During the past decade, several drugs with novel mechanisms of
action and significant activity against NSCLC have been identified,
including paclitaxel, docetaxel, vinorelbine, gemcitabine, and
irinotecan (Lilenbaum and Green, 1993). Combination of one or
two of these agents with a platinum compound has yielded in high
response rate and prolonged survival (Langer et al, 1995; Crino
et al, 1997; Abratt et al, 1998; Le Chevalier et al, 1998; Sandler et al,
2000). The Eastern Cooperative Oncology Group (ECOG) con-
ducted a randomised study to determine whether any of three
chemotherapy regimens was superior to cisplatin and paclitaxel for
patients with advanced NSCLC (ECOG 1594) (Schiller et al, 2002).
A total of 1207 patients with advanced NCSLC were randomly
assigned to a reference regimen of cisplatin and paclitaxel or to
one of three experimental regimens: cisplatin and gemcitabine,
cisplatin and docetaxel, or carboplatin and paclitaxel. Neither
response rate nor survival differed significantly between patients
assigned to receive cisplatin and paclitaxel and those assigned to
receive any of the three experimental regimens. None of the four
chemotherapy regimens offered a significant advantage over the
others in the treatment of advanced NSCLC.
Steps such as weekly administration of taxan, nonplatinum
doublet chemotherapy, triplet chemotherapy, and use of molecular
targeted agents are called for. Among these, weekly administration
of paclitaxel has been introduced to chemotherapy for advanced
NSCLC and several other types of tumours. In vitro experiments
and clinical trials have suggested that prolonged exposure to
paclitaxel, through either continuous infusion schedules or weekly
administration, can lead to enhanced cytotoxicity with main-
tenance of a favourable toxicity profile (Liebmann et al, 1993;
Georgiadis et al, 1997; Zhan et al, 1997). In an attempt to increase
drug exposure time, weekly schedules of intravenous paclitaxel
were initiated and exhibited promising activity and manageable
toxicity for several types of tumours. Akerley et al(2003)
conducted a phase II trial for patients with chemotherapy-naive,
advanced-stage NSCLC. Paclitaxel, 150mgm
 2, was administered
over 3h during weeks 1–6 of an 8-week cycle. In total, 38 patients
were treated. Grades 3–4 granulocytopenia occurred in 39% of
patients. There were no deaths due to toxicity. Grade 2 or 3
neuropathy occurred in 29 and 24% of patients, respectively. There
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lwere 16 partial responses (42%). The median survival period was
12.3 months, and the 1-year and 2-year survival rates were 52 and
26%, respectively. Seidman et al(1998) conducted a clinical trial in
patients with metastatic breast cancer who had received prior
therapy. A total of 30 patients received sustained weekly paclitaxel
therapy at an initial dose of 100mgm
 2. Grade 3/4 neutropenia
occurred in four patients, but febrile neutropenia was not
observed. Peripheral neuropathy prohibited dose escalation above
100mgm
 2, and grade 3 neuropathy was observed in two of 21
patients at p100mgm
 2.
Cisplatin is still the most active drug for NSCLC and
is efficacious when combined with paclitaxel. We therefore
investigated the combination of a weekly paclitaxel and cisplatin
regimen.
PATIENTS AND METHODS
Patient selection
In the phase I study, patients were enrolled if they met the
following criteria: (1) age p75 years, (2) histological or cytological
diagnosis of NSCLC; (3) unresectable stage IIIB or IV disease; (4)
performance status (PS) of 0, 1, or 2 on the ECOG scale with a
predicted life expectancy of at least 12 weeks; (5) measurable or
evaluable disease, (6) no prior or only one regimen of
chemotherapy; (7) any previous chemotherapy or radiation
therapy had been completed more than 4 weeks before enrollment
and patients had recovered from any adverse effects; (8) adequate
major organ function as documented by a WBC count X4000ml
 1,
platelet count X100000ml
 1, haemoglobin X9.5gdl
 1; total
serum bilirubin p1.5mgdl
 1, AST and ALT p2 the institu-
tional upper limit of normal, serum creatinine p1.1mgdl
 1, PaO2
X70Torr, and normal ECG. Written informed consent was
obtained from all patients. Patients were not eligible for study
enrollment in any of the following cases: (1) recent (within the past
3 months) myocardial infarction, uncontrolled angina pectoris, or
arrythmia, (2) uncontrolled hypertension or diabetes, (3) active
infection, (4) pulmonary fibrosis, (5) massive pleural effusion or
ascites, or (6) cerebrovascular disease. In the phase II study,
patients were not eligible if they had previously received
chemotherapy. Other inclusion and exclusion criteria were the
same as for the phase I study.
Treatment plan
The starting dose of paclitaxel was 40mgm
 2week
 1 administered
intravenously (i.v.) on days 1, 8, and 15, increasing
10mgm
 2week
 1 by steps. Paclitaxel was infused i.v. in 250ml
normal saline over 60min. Cisplatin was administered along with a
programe of forced diuresis that included at least 2000ml of fluids
after paclitaxel infusion over 60min on day 1. The cisplatin dose
was fixed at 80mgm
 2. Chemotherapy was given in an every 4-
week cycle and repeated over more than two courses until disease
progression or unacceptable toxicity occurred. Patients were
premedicated with dexamethasone 20mg and ranitidine 50mg
i.v. and were given diphenhydramine 50mg orally 30min before
paclitaxel to prevent hypersensitivity reactions. Prophylactic use of
recombinant granulocyte colony-stimulating factor (rhG-CSF) was
not allowed in the first course and was discouraged during
subsequent courses of treatment. Paclitaxel was withdrawn if the
WBC count was less than 2000ml
 1 and/or the platelet count was
less than 70000ml
 1 on day 8 or 15. Subsequent courses of
chemotherapy were initiated when WBC count X4000ml
 1 and
platelet count was X100000ml
 1 after day 29. If WBC counts or
platelet counts had not returned to these levels on day 1 of the next
course of chemotherapy, both drugs were withheld until full
recovery.
Dose escalation and definition of the maximum-tolerated
dose (MTD) and dose-limiting toxicities (DLT)
Three patients for each cohort were evaluated, and sequential dose
levels were studied in the absence of DLT during the first treatment
cycle. If one or two of the three patients at any dose level
experienced DLT, three additional patients were added at that level
before escalation. There was no dose escalation for individual
patients. The MTD of the combination was defined as the dose
level below that which produced DLT in more than one-third of
treated patients. Toxicities were graded using the National Cancer
Institute common toxicity criteria, version 2.0. Dose-limiting
toxicities was defined as (1) febrile neutropenia (fever X381C
with Xgrade 3 neutropenia), (2) grade 4 neutropenia (X4 days)
despite receiving rhG-CSF, (3) grade 4 thrombocytopenia, (4) any
other grade 3 or 4 nonhaematologic toxicity (except nausea,
vomiting, or alopecia), (5) failure to recover from toxicities
sufficiently to begin a second course of treatment by day 43, and
omission of chemotherapy on day 8 and/or 15 because of toxities.
MTD and RD were determined from the toxicity during the first
cycle of treatment.
Dose modifications
In phase I, doses were not reduced or escalated in individual
patients. In phase II, subsequent doses were modified on the basis
of haematological and nonhaemotological toxicities. If toxicities
were observed during the previous cycle, toxicities were observed,
the dose of pacitaxel was reduced by 10mgm
 2. Toxicity was
defined as DLTs in the phase I study ((1) febrile neutropenia (fever
X381C with Xgrade 3 neutropenia), (2) grade 4 neutropenia (X4
days) despite receiving rhG-CSF, (3) grade 4 thrombocytopenia,
(4) any other grade 3 or 4 nonhaematologic toxicity (except
nausea, vomiting, or alopecia), (5) omission of chemotherapy on
day 8 and/or 15 because of toxicity).
Patient evaluation
Patients were evaluated to determine clinical stage by complete
medical history and physical examination, routine chest radio-
graphy, bone scintiscan, and computerised tomography of the
head, chest, and abdomen. Before the first course, each patient was
subject to complete blood count (CBC), including differential
count and platelet count, and serum chemistry was used to check
renal and hepatic functions, electrolytes and urinalysis. CBC,
serum chemistry, electrolytes, urinalysis, and chest radiographs
were assessed at least once a week after the initial evaluation. Other
appropriate investigations were repeated biweekly or every 4 weeks
to evaluate the sites of marker lesions. After completion of
chemotherapy, each patient was restaged with all the tests used
during the initial work-up.
Tumour response was assessed according to the World Health
Organization criteria (WHO, 1979). Tumours were reassessed
during treatment with the same imaging method used to obtain
baseline tumour measurement. Whenever possible, patients with
evidence of tumour response were to have confirmation within 4–
6 weeks after initial documentation of response. In addition, time
to response, duration of response, time to tumour progression, and
survival were determined. External radiology review was per-
formed for all patients.
Statistics
The 95% confidence intervals (CIs) for estimated response rate
were calculated using the binomial distribution. Time-to-event
probability curves and the probability of survival at 1 year were
estimated using the Kaplan–Meier methods.
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Patient characteristics
In the phase I study, a total of 18 patients were enrolled between
July 2000 and February 2001 (Table 1). A total of 18 were
assessable for toxicity. There were 10 men and eight women with a
median age of 63 years (range, 47–73). A total of 15 patients had
stage IV and three had stage IIIB disease. Adenocarcinoma was the
most common histology (n¼12), followed by squamous cell
carcinoma (n¼6). Four patients had received prior chemotherapy.
Three of these patients had received a combination of cisplatin and
docetaxel, and one had received vinorelbin alone. Three patients
had received prior chemoradiotherapy. Two of them had received
weekly carboplatinþirinotecan and concurrent radiotherapy, and
the other had received daily carboplatin and concurrent radio-
therapy.
In the phase II study, a total of 20 patients were enrolled
between April 2001 and December 2001 (Table 1). In total,
20patients were assessable for toxicity and efficacy. There were 16
men and four women with a median age of 67 years (range, 53–
74). A total of 16 patients had stage IV and four had stage IIIB
disease. None of the patients had received prior chemotherapy.
Toxicities
For the phase I study, haematologic toxicities and nonhaemato-
logic toxicities are listed in Table 2. At the dose level of 50mgm
 2,
two patients experienced DLT. One had paclitaxel administration
omitted on day 15 due to leucopenia, and the other developed
febrile neutropenia. Three additional patients were added and
none experienced DLT. At 60mgm
 2, one experienced grade 3
nausea. At 70mgm
 2, three patients were initially enrolled, and
one developed grade 3 fatigue and had paclitaxel administration
omitted on day 8 due to thrombocytopenia. Three additional
patients were therefore added. Of the three, two experienced DLT.
One developed grade 4 neutropenia lasting more than 4 days
despite receiving rhG-CSF, and one had paclitaxel administration
omitted on day 15 due to leucopenia. This dose level was
determined to be the MTD, and the RD of phase II was estimated
to be this dose as well.
In the phase I study, there were a total of 45 cycles of treatment
in 18 patients. The median number of cycles was two (range, one to
four). Six cycles (13%) were delayed by more than 6 days due to
treatment toxicity.
In the phase II study, the 20 patients assessable for safety
received a total of 47 cycles of therapy. The median number of
cycles was two (range, one to five). Six (13%) of the cycles of
treatment were delayed by more than 6 days due to treatment
toxicity.
For the phase II study, Table 3 lists the overall incidence of
haematologic and nonhaematologic toxicities for all patients
treated in all cycles. Grade 3/4 neutropenia was the most common
adverse event and occurred in 40% of the patients. None of the
patients had grade 3/4 thrombocytopenia. During treatment, only
two patients (10%) had febrile neutropenia, which was defined as
Xgrade 1 fever with Xgrade 3 neutropenia. Five (25%) patients
received rhG-CSF during study treatment. The major nonhaema-
tologic grade 3/4 adverse events occurring in seven (35%) of the
patients were infection (three; 15%), fatigue (two; 10%), and
anorexia. Grade 1/2 peripheral neuropathy occurred in only two
Table 1 Patients characteristics for phase I/II
Characteristics Phase I Phase II Total
Patients entered 18 20 38
Age (years)
Median 63 67 67
Range 47–73 53–74 47–74
Gender
Male 10 16 26
Female 8 4 12
PS
03 0 3
11 3 1 9 3 2
22 1 3
Stage
IIIB 3 4 7
IV 15 16 31
Histology
Adenocarcinoma 12 10 22
Squamous cell carcinoma 6 9 15
Large cell carcinoma 0 1 1
Prior therapy
Chemotherapy 4 0 4
Chemoradiotherapy 3 0 3
Radiotherapy 0 2 2
Surgery 2 4 6
None 9 14 23
Table 2 Toxicity for phase I
Level 1 (n¼3) Level 2 (n¼6) Level 3 (n¼3) Level 4 (n¼6)
Grade Grade Grade Grade
Toxicity 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
Leucocytopenia — — — — — — — — — — — — — — — —
Neutropenia — — — — 1 2 2 1 1 2 — — — 1 1 2
Febrile neutropenia — — — — — — — — — — 1 — — — — —
Thrombocytopenia — — — — 2 — — — — — — — — 1 — —
Anaemia — — — — — — — — — — — — — — — —
Nausea 3 — — — 3 — — — 2 — 1 — 1 3 — —
Vomiting — — — — 3 — — — — — — — 1 1 — —
Anorexia 3 — — — 5 — — — 1 — — — 2 3 — —
Fatigue — — — — — — — — — — — — 2 — 1 —
Neuropathy — — — — — — — — — — — — 1 — — —
Alopecia — — — — 2 — — — — 1 — — 3 — — —
Elevated AST/ALT — — — — — 2 — — 1 — — — — — — —
Elevated g- G T P ————— 1 —— 1 ———————
Allergic reaction — — — — — — — — — — — — — 1 — —
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observed in any patient. Fatigue was a cumulative toxicity
observed during this trial. Five (25%) of 20 patients in the first
course, six (40%) of 15 patients in the second course, four (57%) of
seven patients in the third course, three (75%) of seven patients
(75%) in the fourth course, and one (100%) of one patient in the
fifth had fatigue.
Efficacy
In the phase I and II studies, 37 patients were evaluable for
response. Overall, one complete response and 23 partial responses
were recorded, for a 62.1% (95% confidence interval: 46.5–77.7)
objective response rate (Table 4). One patient could not be
evaluated for response. She was found to have pathological N3
disease after the prior surgery. Chemotherapy was performed in
the adjuvant setting and she did not have any measurable lesions.
Five partial responses occurred in the seven patients who had
received prior systemic chemotherapy.
The median time to tumour progression was 5.5 months (range,
0.4–23.2 months), and the median survival was 13.7 months
(range, 0.5–23.9 months). The 1-year survival rate was 56.9%. The
Kaplan–Meier survival curve and time to tumour progression
curve for the 38 assessable patients are shown in Figure 1.
Dose-intensity
In the phase I study, the projected dose-intensities of paclitaxel at
dose levels 1–4 were 30, 37.5, 45, and 52.5mgm
 2week
 1. The
actual dose-intensities of paclitaxel at each dose level were
29.5(98%), 32.6(87%), 32.1(71%), and 36.7(70%) mgm
 2 week
 1.
The projected dose-intensity of cisplatin at dose levels 1–4 was
20mgm
 2week
 1. The actual dose-intensities of cisplatin at each
dose level were 19.7(98%), 18.5(93%), 16.5(83%), and 18.7(89%)
mgm
 2 week
 1.
In the phase II study, the projected dose-intensity of paclitaxel
was 52.5mgm
 2week
 1. The actual dose-intensity of paclitaxel
was 41.6mgm
 2 week
 1 (79.2%). The projected dose-intensity of
cisplatin was 20.0mgm
 2week
 1. The actual dose-intensity of
cisplatin at each dose level was 19.2 (96.0%) mgm
 2
week
 1(Table 5).
DISCUSSION
As did ECOG 1594, other clinical oncology groups such as the
Southwestern Oncology Group, Italian Lung Cancer Project, and
Table 3 Toxicity in all cycles for phase II
Grade 1 Grade 2 Grade 3 Grade 4
Toxicity No. % No. % No. % No. %
Leucocytopenia 4 20 8 40 5 25 —
Neutropenia 3 15 5 25 6 30 2 10
Febrile neutropenia — — 2 10 —
Thrombocytopenia 7 35 — — —
Anaemia 5 25 12 60 3 15 —
Nausea 11 55 4 20 1 5 —
Vomiting 5 25 3 15 — —
Anorexia 14 70 2 10 2 10 —
Fatigue 5 15 2 10 2 10 —
Neuropathy 1 5 1 5 — —
Alopecia 10 50 9 45 — —
g-GTP — — 1 5 —
Allergic reaction — — 1 5 —
Constipation 1 5 1 5 — —
Fever up 1 5 — — —
Creatinine 1 5 — — —
Flushing 1 5 — — —
Infection — — 3 15 —
Arrythmia — — 1 5 —
Cerebral infarction — — — 1 5
Table 4 Response for phase I/II
Dose level n CR PR SD PD NE ORR (%)
Phase 1
Level 1 3(2) — 1(1) 2(1) 0 0 33.3
Level 2 6(3) — 4(3) 1(0) 0 1(0) 67.8
Level 3 3(1) — 2(1) 0 1(0) 0 67.8
Level 4 6(1) — 5(0) 0 1(1) 0 83.3
Total 18(7) — 12(5) 3(1) 2(1) 1(0) 70.6
Phase II 20(0) 1(0) 11(0) 6(0) 2(0) 0(0) 55.0
Phase I/II 38(7) 1(0) 23(5) 9(1) 2(1) 1(0) 62.1
( ): number of pretreated patients, n¼number of patients, CR¼complete response,
PR¼partial response, SD¼stable disease, PD¼progression disease, NE¼not
evaluable, ORR¼objective response rate.
Figure 1 Kaplan–Meier survival curve (—) and time to tumour
progression curve (?) for the 38 assessable patients are shown. The
progression-free survival, median survival time, and 1-year survival rate
were 5.5 months, 13.7 months, and 56.9%, respectively. The symbols (þ)
are for censored patients.
Table 5 Dose intensity for phase I/II
PDI
(mgm
 2week
 1)
ADI
(mgm
 2week
 1)
RDI
(mgm
 2week
 1)
CDDP PTX CDDP PTX CDDP PTX
Phase I
Level 1 20.0 30.0 19.7 29.5 0.98 0.98
Level 2 20.0 37.5 18.5 32.6 0.93 0.87
Level 3 20.0 45.0 16.5 32.1 0.83 0.71
Level 4 20.0 52.5 17.8 36.7 0.89 0.70
Phase II
20.0 52.5 19.2 41.6 0.96 0.79
PDI¼projected dose intensity; ADI¼actual dose intensity; RDI¼relative dose
intensity; CDDP¼cisplatin; PTX¼paclitaxel.
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lEuropean Organization for Research and Treatment of Cancer
conducted randomised studies to determine whether any new drug
plus a platinum compound offered a survival advantage
over another reference arm for patients with advanced NSCLC
(Kelly et al, 2001; Scagliotti et al, 2002; Schiller et al, 2002;
Smit et al, 2003). None of the chemotherapy regimens tested
offered a significant advantage over the others in the treatment
of advanced NSCLC. As a next step in chemotherapy for advanced
NSCLC, we investigated a combined weekly paclitaxel and cisplatin
regimen. Dose-limiting toxicities were neutropenia, fatigue,
and omission of treatment on day 15 due to leucopenia,
thrombocytopenia, and febrile neutropenia. The MTD and RD of
paclitaxel were estimated to be 70mgm
 2. For the 37 assessable
patients, the overall response rate was 62.1%. The median survival
time and the 1-year survival rate were 13.7 months and 56.9%,
respectively. This regimen is thus tolerable and very active against
advanced NSCLC.
Carboplatin has been used instead of cisplatin in chemotherapy
for NSCLC. Some studies reported that carboplatin combined with
weekly paclitaxel was a new and active treatment regimen (Belani,
2001). A phase III study of chemotherapy-naive advanced NSCLC
patients was designed to assess whether efficacy in patients
receiving a paclitaxel/carboplatin combination was similar to that
in patients receiving a paclitaxel/cisplatin combination (Rosell
et al, 2002). The authors concluded that paclitaxel/cisplatin yielded
a response rate similar to and median survival significantly longer
than paclitaxel/carboplatin. These results suggested that cisplatin-
based chemotherapy should be the first treatment option for
NSCLC. We therefore used cisplatin instead of carboplatin in
combination with paclitaxel.
Akerley et al(2003) conducted a phase II trial for patients with
chemotherapy-naive, advanced-stage NSCLC. Paclitaxel,
150mgm
 2, was administered over 3h during weeks 1–6 of an
8-week cycle. A total of 38 patients were treated. Grade 3/4
granulocytopenia occurred in 39% of patients. There were no
deaths due to toxicity. Grade 2 or 3 neuropathy occurred in 29 and
24% of patients, respectively. Grade 2/3 anorexia and nausea
occurred in 11 and 8% of patients, respectively. In our phase II
study, in all cycles grade 3/4 neutropenia was the most common
adverse event and occurred in 40% of patients. Neuropathy was
mild, at grade 1 or 2 (10%). On the other hand, grade 2/3 anorexia
and nausea occurred in four (20%) and five (25%) patients,
respectively. Although cisplatin was added in our regimen, the
frequency of gastrointestinal toxicity was generally equivalent to
that with a weekly paclitaxel regimen. Peripheral neuropathy and
allergic reaction were mild compared with those associated with
paclitaxel weekly regimen, as a result of the low dose of paclitaxel
used in our regimen.
As a standard arm for NSCLC in a phase III study, 175mgm
 2
of paclitaxel, administered over a 3-h period on day 1, followed by
80mgm
 2 of cisplatin on day 1 every 21 days, is used (Giaccone,
2002). Grade 4 neutropenia was observed in 8.8% of patients
treated with this regimen and 10% of patients treated with our
regimen. Grade 3 febrile neutropenia was observed in 1.9% of
patients treated with that regimen and 10% of patients treated with
our regimen. Grade 3 sensory neuropathy was observed in 2.5% of
patients treated with that regimen, while grade 3 neuropathy was
seen in no patients treated with our regimen. Grade 3 nausea was
observed in 6.3% of patients treated with that regimen and 5% of
patients treated with our regimen. It appears that grade 3 febrile
neutropenia was more common with our weekly regimen, but that
grade 3 neuropathy was more common with the standard regimen.
Weekly administration of paclitaxel appears to yield results similar
to those of the 3-week schedule administered over a 3-h period
with good tolerability.
In the four-arm ECOG trial, for patients who received cisplatin
and paclitaxel, overall response rate was 21%, median survival was
7.8 months, and 1-year and 2-year survival rates were 31 and 10%,
respectively (Schiller et al, 2002).
In the three-arm EORTC trial, for the patients who received
cisplatin and paclitaxel, overall response rate was 31.8%, median
survival was 8.1 months, and 1-year survival rate was 35.9% (Smit
et al, 2003). In our regimen, overall response rate was 62.1%,
median survival was 13.7 months, and 1-year survival rate was
56.9%. Although the response rate is definitely higher than all of
those for the combinations of cisplatin and paclitaxel thus far
published, because our phase I/II study was very small in size,
there might have been patient selection bias, and seven patients
(18.9%) had stage IIIB disease.
In conclusion, we investigated the combination of a weekly
paclitaxel and cisplatin regimen. The combination yielded a high
response rate, with modest side effects. A phase III study
comparing this regimen with 3-week schedule of paclitaxel and
cisplatin or carboplatin needs to be performed.
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